PhDCarlMakiCarl Maki349531Maki, CarlMy Scopus number is 35561716200.
My NIH COMMONS name is CGMAKI.
My Faculty Profile at Rush University Medical Center:
https://www.rushu.rush.edu/faculty/carl-maki-phd
My Laboratory:
https://www.rushu.rush.edu/research/departmental-research/cell-molecular-medicine-research/laboratory-carl-maki-phd
My NCBI Bibliography:
https://www.ncbi.nlm.nih.gov/pubmed/?term=Maki+CG
My Scopus:
https://www.scopus.com/authid/detail.uri?authorId=35561716200
Education:
PhD, Kansas State UniversityProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifierbibo:suffixNamename suffixAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:orcidIdORCID idvivo:overviewoverviewvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 33178330289354Duan L, Perez RE, Maki CGCancer biology & therapyAlpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biol Ther. 2019; 20(3):252-260.Cancer Biol Ther2018-10-05T00:00:002018Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a.Authorship 35098630967636Duan L, Perez RE, Chastain PD, Mathew MT, Bijukumar DR, Maki CGOncogeneJMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657.Oncogene2019-04-09T00:00:002019JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.Authorship 35298531036564Duan L, Perez RE, Lai X, Chen L, Maki CGThe Journal of biological chemistryThe histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells. J Biol Chem. 2019 06 07; 294(23):9186-9197.J Biol Chem2019-04-29T00:00:002019The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.D007093Chemicals & Drugs32720.937642ImidazolesKalipadaPahanKalipada Pahan349039Pahan, KalipadaProfessortrue1ProfessorProfessorPathologyStevenGitelisSteven Gitelis41.87352120000000-87.66713820000000349068Gitelis, StevenProfessorPhilipBonomiPhilip Bonomi349183Bonomi, PhilipProfessorLeiDuanLei Duan349250Duan, LeiAssistant ProfessorPaoloGattusoPaolo Gattuso349288Gattuso, PaoloProfessorChicago60612IL1168selected publications11.19460.00603901346research areas14.08710.2156855coauthor of167.6097.8564360similar toJeffreyBorgiaJeffrey A. Borgia349549Borgia, JeffreyAssociate ProfessorLotharBlatterLothar Blatter41.87432800000000-87.67059170000000349611Blatter, LotharProfessor6Assistant Professor5Associate Professor4Professortrue1ProfessorProfessor24936056Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CGThe Journal of biological chemistryThe prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem. 2014 Aug 01; 289(31):21694-705.J Biol Chem2014-06-16T00:00:002014The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT.24959378Lu Y, Gitelis S, Lei G, Ding M, Maki C, Mira RR, Zheng QAmerican journal of cancer researchResearch findings working with the p53 and Rb1 targeted osteosarcoma mouse model. Am J Cancer Res. 2014; 4(3):234-44.Am J Cancer Res2014-05-26T00:00:002014Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model.25069039Duan L, Danzer B, Levenson VV, Maki CGCancer lettersCritical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells. Cancer Lett. 2014 Oct 28; 353(2):290-300.Cancer Lett2014-07-25T00:00:002014Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells.25482935Duan L, Perez RE, Hansen M, Gitelis S, Maki CGCancer biology & therapyIncreasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther. 2014; 15(12):1600-12.Cancer Biol Ther2014-01-01T00:00:002014Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.26337205Duan L, Perez RE, Davaadelger B, Dedkova EN, Blatter LA, Maki CGOncotargetp53-regulated autophagy is controlled by glycolysis and determines cell fate. Oncotarget. 2015 Sep 15; 6(27):23135-56.Oncotarget2015-09-15T00:00:002015p53-regulated autophagy is controlled by glycolysis and determines cell fate.26799652Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Alg?l H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, B?nhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolom? A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, B?dard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, B?nard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, B?ckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouch? M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, B?tikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ce?a V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, et alAutophagyGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222.Autophagy2016-01-01T00:00:002016Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).27022024Perez RE, Shen H, Duan L, Kim RH, Kim T, Park NH, Maki CGThe Journal of biological chemistryModeling the Etiology of p53-mutated Cancer Cells. J Biol Chem. 2016 May 06; 291(19):10131-47.J Biol Chem2016-03-28T00:00:002016Modeling the Etiology of p53-mutated Cancer Cells.27050276Davaadelger B, Duan L, Perez RE, Gitelis S, Maki CGOncotargetCrosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016 May 10; 7(19):27511-26.Oncotarget2016-05-10T00:00:002016Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.D051736Chemicals & Drugs5290.976608Proto-Oncogene Proteins c-mdm2Authorship 392811Authorship 393013Authorship 396463Authorship 396494Authorship 39656211359801Ohteki T, Maki C, Koyasu SJournal of immunology (Baltimore, Md. : 1950)Overexpression of Bcl-2 differentially restores development of thymus-derived CD4-8+ T cells and intestinal intraepithelial T cells in IFN-regulatory factor-1-deficient mice. J Immunol. 2001 Jun 01; 166(11):6509-13.J Immunol2001-06-01T00:00:002001Overexpression of Bcl-2 differentially restores development of thymus-derived CD4-8+ T cells and intestinal intraepithelial T cells in IFN-regulatory factor-1-deficient mice.11702064Ohteki T, Suzue K, Maki C, Ota T, Koyasu SNature immunologyCritical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response. Nat Immunol. 2001 Dec; 2(12):1138-43.Nat Immunol2001-12-01T00:00:002001Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response.2507396Maki C, Rhoads DD, Stewart MJ, Van Slyke B, Roufa DJGeneThe Drosophila melanogaster RPS17 gene encoding ribosomal protein S17. Gene. 1989 Jul 15; 79(2):289-98.Gene1989-07-15T00:00:001989The Drosophila melanogaster RPS17 gene encoding ribosomal protein S17.9581850Nagasawa H, Keng P, Maki C, Yu Y, Little JBCancer researchAbsence of a radiation-induced first-cycle G1-S arrest in p53+ human tumor cells synchronized by mitotic selection. Cancer Res. 1998 May 01; 58(9):2036-41.Cancer Res1998-05-01T00:00:001998Absence of a radiation-induced first-cycle G1-S arrest in p53+ human tumor cells synchronized by mitotic selection.10377194Ohteki T, Fukao T, Suzue K, Maki C, Ito M, Nakamura M, Koyasu SThe Journal of experimental medicineInterleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J Exp Med. 1999 Jun 21; 189(12):1981-6.J Exp Med1999-06-21T00:00:001999Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells.Authorship 106415Authorship 107973Authorship 109113Authorship 111087Authorship 111745Authorship 113735Authorship 116602Authorship 117633Authorship 119593Authorship 120914Authorship 134923Authorship 136063Authorship 143871323Authorship 145043Authorship 146122Authorship 147132Authorship 147531Authorship 154386Authorship 158641Authorship 162624Authorship 169632Authorship 170687Authorship 172863Authorship 180733Authorship 185402Authorship 189577Authorship 190344Authorship 19092412759344Wei X, Yu ZK, Ramalingam A, Grossman SR, Yu JH, Bloch DB, Maki CGThe Journal of biological chemistryPhysical and functional interactions between PML and MDM2. J Biol Chem. 2003 Aug 01; 278(31):29288-97.J Biol Chem2003-05-19T00:00:002003Physical and functional interactions between PML and MDM2.12777718Jardine LJ, Maki CGMethods in molecular biology (Clifton, N.J.)Stability and ubiquitination of the tumor suppressor protein p53. Methods Mol Biol. 2003; 223:27-38.Methods Mol Biol2003-01-01T00:00:002003Stability and ubiquitination of the tumor suppressor protein p53.14507915Zhu H, Wu L, Maki CGThe Journal of biological chemistryMDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53. J Biol Chem. 2003 Dec 05; 278(49):49286-92.J Biol Chem2003-09-24T00:00:002003MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53.15021899Wu L, Zhu H, Nie L, Maki CGOncogeneA link between p73 transcriptional activity and p73 degradation. Oncogene. 2004 May 13; 23(22):4032-6.Oncogene2004-05-13T00:00:002004A link between p73 transcriptional activity and p73 degradation.D051057Chemicals & Drugs28560.945068Proto-Oncogene Proteins c-akt15964852Zhu H, Nie L, Maki CGThe Journal of biological chemistryCdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem. 2005 Aug 12; 280(32):29282-8.J Biol Chem2005-06-17T00:00:002005Cdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif.16115632Inoue T, Wu L, Stuart J, Maki CGFEBS lettersControl of p53 nuclear accumulation in stressed cells. FEBS Lett. 2005 Sep 12; 579(22):4978-84.FEBS Lett2005-09-12T00:00:002005Control of p53 nuclear accumulation in stressed cells.17064981Maki CGLeukemia & lymphomaP53 gene alterations identified in classical Hodgkin's lymphoma cell lines. Leuk Lymphoma. 2006 Sep; 47(9):1734-5.Leuk Lymphoma2006-09-01T00:00:002006P53 gene alterations identified in classical Hodgkin's lymphoma cell lines.17150106Zhang L, Nie L, Maki CGMolecular cancerP53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity. Mol Cancer. 2006 Dec 06; 5:68.Mol Cancer2006-12-06T00:00:002006P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.17363365Sasaki M, Nie L, Maki CGThe Journal of biological chemistryMDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem. 2007 May 11; 282(19):14626-34.J Biol Chem2007-03-15T00:00:002007MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation.17371868Nie L, Sasaki M, Maki CGThe Journal of biological chemistryRegulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem. 2007 May 11; 282(19):14616-25.J Biol Chem2007-03-19T00:00:002007Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination.18922897Shen H, Moran DM, Maki CGCancer researchTransient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008 Oct 15; 68(20):8260-8.Cancer Res2008-10-15T00:00:002008Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells.19409099Moran DM, Shen H, Maki CGBMC cell biologyPuromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes. BMC Cell Biol. 2009 May 01; 10:32.BMC Cell Biol2009-05-01T00:00:002009Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes.20371712Moran DM, Maki CGMolecular cancer therapeuticsNutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):895-905.Mol Cancer Ther2010-04-06T00:00:002010Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells.20489208Shen H, Maki CGThe Journal of biological chemistryPersistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem. 2010 Jul 23; 285(30):23105-14.J Biol Chem2010-05-20T00:00:002010Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells.20603526Maki CGAgingDecision-making by p53 and mTOR. Aging (Albany NY). 2010 Jun; 2(6):324-6.Aging (Albany NY)2010-06-01T00:00:002010Decision-making by p53 and mTOR.20803550Shen H, Maki CGJournal of cellular biochemistryp53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem. 2010 Dec 01; 111(5):1280-90.J Cell Biochem2010-12-01T00:00:002010p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.21391906Shen H, Maki CGCurrent pharmaceutical designPharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des. 2011; 17(6):560-8.Curr Pharm Des2011-01-01T00:00:002011Pharmacologic activation of p53 by small-molecule MDM2 antagonists.22773829Aziz MH, Shen H, Maki CGThe Journal of biological chemistryGlucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Ce. J Biol Chem. 2012 Aug 24; 287(35):29825-36.J Biol Chem2012-07-06T00:00:002012Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Ce.23560058Shen H, Perez RE, Davaadelger B, Maki CGPloS oneTwo 4N cell-cycle arrests contribute to cisplatin-resistance. PLoS One. 2013; 8(4):e59848.PLoS One2013-04-01T00:00:002013Two 4N cell-cycle arrests contribute to cisplatin-resistance.25380055Davaadelger B, Shen H, Maki CGPloS oneNovel roles for p53 in the genesis and targeting of tetraploid cancer cells. PLoS One. 2014; 9(11):e110844.PLoS One2014-11-07T00:00:002014Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.Authorship 41314633044914Perez RE, Calhoun S, Shim D, Levenson VV, Duan L, Maki CGCancer biology & therapyProlyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer. Cancer Biol Ther. 2020 11 01; 21(11):1033-1040.Cancer Biol Ther2020-10-12T00:00:002020Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer.Internal MedicineNeurological SciencesOrthopedic SurgeryAnatomy and Cell BiologyRush University, Rush Medical CollegeDavidBennettDavid A. Bennett41.87328300000000-87.66936330000000349004Bennett, DavidProfessorJamesMulshineJames L. Mulshine41.87328300000000-87.66936330000000349025Mulshine, James0000-0002-4648-9177ProfessorAuthorship 41700633755174Duan L, Calhoun S, Shim D, Perez RE, Blatter LA, Maki CGJournal of molecular cell biologyFatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 09 11; 13(6):433-444.J Mol Cell Biol2021-09-11T00:00:002021Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells.Authorship 43392334532654Shim D, Duan L, Maki CGCancer drug resistance (Alhambra, Calif.)P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4:85-95.Cancer Drug Resist2021-03-19T00:00:002021P53-regulated autophagy and its impact on drug resistance and cell fate.D010879Chemicals & Drugs36900.920561Piperazinestrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate ProfessorAuthorship 439409Authorship 439486Authorship 439603Authorship 439724Authorship 440864Authorship 445123Authorship 44553435092683Duan L, Calhoun S, Shim D, Perez RE, Blatter LA, Maki CGJournal of molecular cell biologyCorrigendum to 'Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells'. J Mol Cell Biol. 2022 Jan 29; 13(12):922.J Mol Cell Biol2022-01-29T00:00:002022Corrigendum to 'Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells'.35058503Duan L, Perez RE, Calhoun S, Maki CGScientific reportsRBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.Sci Rep2022-01-20T00:00:002022RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC.35100078Duan L, Perez RE, Calhoun S, Maki CGCancer biology & therapyInhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75.Cancer Biol Ther2022-12-31T00:00:002022Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.35159006Duan L, Calhoun S, Perez RE, Macias V, Mir F, Pergande MR, Gattuso P, Borgia JA, Maki CGCancersProlyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers (Basel). 2022 Jan 31; 14(3).Cancers (Basel)2022-01-31T00:00:002022Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer.35263700Calhoun S, Duan L, Maki CGTranslational oncologyAcetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells. Transl Oncol. 2022 May; 19:101386.Transl Oncol2022-03-06T00:00:002022Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells.35296774Duan L, Perez RE, Calhoun S, Maki CGScientific reportsAuthor Correction: RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 Mar 16; 12(1):4525.Sci Rep2022-03-16T00:00:002022Author Correction: RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC.35582378Shim D, Duan L, Maki CGCancer drug resistance (Alhambra, Calif.)Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4(4):903.Cancer Drug Resist2021-09-23T00:00:002021Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate.Internal Medicine, Division of Hematology/Oncology/Cell Therapytrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorPhysiology and BiophysicsAuthorship 274736Authorship 274743Authorship 274755Authorship 274765Authorship 274772Authorship 274784Authorship 274793Authorship 274803Authorship 274814Authorship 274824Authorship 274831Authorship 274841Authorship 274851Authorship 274863Authorship 274871Authorship 274883Authorship 29046228696156Davaadelger B, Perez RE, Zhou Y, Duan L, Gitelis S, Maki CGCancer biology & therapyThe IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017 Nov 02; 18(11):895-903.Cancer Biol Ther2017-07-11T00:00:002017The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.21643018Aziz MH, Shen H, Maki CGOncogeneAcquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene. 2011 Nov 17; 30(46):4678-86.Oncogene2011-06-06T00:00:002011Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.18504430Moran DM, Gawlak G, Jayaprakash MS, Mayar S, Maki CGOncogeneGeldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene. 2008 Sep 18; 27(42):5567-77.Oncogene2008-05-26T00:00:002008Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells.11572869Inoue T, Geyer RK, Howard D, Yu ZK, Maki CGThe Journal of biological chemistryMDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem. 2001 Nov 30; 276(48):45255-60.J Biol Chem2001-09-25T00:00:002001MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding.11342211Tasheva ES, Maki CG, Conrad AH, Conrad GWBiochimica et biophysica actaTranscriptional activation of bovine mimecan by p53 through an intronic DNA-binding site. Biochim Biophys Acta. 2001 Feb 16; 1517(3):333-8.Biochim Biophys Acta2001-02-16T00:00:002001Transcriptional activation of bovine mimecan by p53 through an intronic DNA-binding site.11223035Inoue T, Geyer RK, Yu ZK, Maki CGFEBS lettersDownregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett. 2001 Feb 16; 490(3):196-201.FEBS Lett2001-02-16T00:00:002001Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents.11127820Yu ZK, Geyer RK, Maki CGOncogeneMDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene. 2000 Nov 30; 19(51):5892-7.Oncogene2000-11-30T00:00:002000MDM2-dependent ubiquitination of nuclear and cytoplasmic P53.10980696Geyer RK, Yu ZK, Maki CGNature cell biologyThe MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2000 Sep; 2(9):569-73.Nat Cell Biol2000-09-01T00:00:002000The MDM2 RING-finger domain is required to promote p53 nuclear export.10768862Geyer RK, Nagasawa H, Little JB, Maki CGCell growth & differentiation : the molecular biology journal of the American Association for Cancer ResearchRole and regulation of p53 during an ultraviolet radiation-induced G1 cell cycle arrest. Cell Growth Differ. 2000 Mar; 11(3):149-56.Cell Growth Differ2000-03-01T00:00:002000Role and regulation of p53 during an ultraviolet radiation-induced G1 cell cycle arrest.10626788Alarc?n R, Koumenis C, Geyer RK, Maki CG, Giaccia AJCancer researchHypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999 Dec 15; 59(24):6046-51.Cancer Res1999-12-15T00:00:001999Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.10347217Maki CGThe Journal of biological chemistryOligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem. 1999 Jun 04; 274(23):16531-5.J Biol Chem1999-06-04T00:00:001999Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2.8972216Maki CG, Howley PMMolecular and cellular biologyUbiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol. 1997 Jan; 17(1):355-63.Mol Cell Biol1997-01-01T00:00:001997Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation.8653711Maki CG, Huibregtse JM, Howley PMCancer researchIn vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996 Jun 01; 56(11):2649-54.Cancer Res1996-06-01T00:00:001996In vivo ubiquitination and proteasome-mediated degradation of p53(1).7728750Nagasawa H, Li CY, Maki CG, Imrich AC, Little JBCancer researchRelationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Res. 1995 May 01; 55(9):1842-6.Cancer Res1995-05-01T00:00:001995Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells.2388616Maki CG, Rhoads DD, Diaz JJ, Roufa DJMolecular and cellular biologyA Drosophila ribosomal protein functions in mammalian cells. Mol Cell Biol. 1990 Sep; 10(9):4524-8.Mol Cell Biol1990-09-01T00:00:001990A Drosophila ribosomal protein functions in mammalian cells.2210388Brown SJ, Jewell A, Maki CG, Roufa DJGeneA cDNA encoding human ribosomal protein S24. Gene. 1990 Jul 16; 91(2):293-6.Gene1990-07-16T00:00:001990A cDNA encoding human ribosomal protein S24.28966916Duan L, Maki CGTranslational cancer researchThe IGF-1R/AKT pathway determines cell fate in response to p53. Transl Cancer Res. 2016 Dec; 5(6):664-675.Transl Cancer Res2016-12-01T00:00:002016The IGF-1R/AKT pathway determines cell fate in response to p53.Authorship 29399529190376Duan L, Perez RE, Chen L, Blatter LA, Maki CGJournal of molecular cell biologyp53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340.J Mol Cell Biol2018-08-01T00:00:002018p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.Authorship 4708612Authorship 464717Authorship 46863336095190Kumar S, Das S, Sun J, Huang Y, Singh SK, Srivastava P, Sondarva G, Nair RS, Viswakarma N, Ganesh BB, Duan L, Maki CG, Hoskins K, Danciu O, Rana B, Li S, Rana AProceedings of the National Academy of Sciences of the United States of AmericaMixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles. Proc Natl Acad Sci U S A. 2022 09 20; 119(38):e2205454119.Proc Natl Acad Sci U S A2022-09-12T00:00:002022Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles.36332175Duan L, Calhoun SJ, Perez RE, Macias V, Mir F, Gattuso P, Maki CGCancer biology & therapyProlylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. Cancer Biol Ther. 2022 Dec 31; 23(1):1-10.Cancer Biol Ther2022-12-31T00:00:002022Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer.37759078Duan L, Tadi MJ, Maki CGScientific reportsCSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271.Sci Rep2023-09-27T00:00:002023CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor.Authorship 31469429394130Zhou Y, Perez RE, Duan L, Maki CGCancer biology & therapyDZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a. Cancer Biol Ther. 2018 06 03; 19(6):465-474.Cancer Biol Ther2018-03-13T00:00:002018DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a.D016159Chemicals & Drugs25890.913828Tumor Suppressor Protein p53